Latest Administration News

Sequoia Financial Group reported a robust FY25 with a 13.7% rise in EBITDA and a 44% jump in funds under advice, underpinned by strategic restructuring and technology investments.

Sequoia Financial Group reported a 13.7% rise in operating profit for FY25, driven by significant growth in funds under advice and operational efficiencies. The company declared a fully franked final dividend, signaling confidence despite ongoing regulatory investigations.

Sequoia Financial Group reported steady revenue but a sharp profit decline in FY25, driven by divestments and goodwill impairment. The company simplified its business structure and strengthened governance while maintaining dividend payouts.

RAS Technology Holdings Limited reported a robust 31% revenue increase to $21.3 million in FY25, achieving its first after-tax profit following a strategic acquisition in Hong Kong that expanded its Asian footprint and recurring revenue.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

Lifestyle Communities reported a challenging FY25 with a significant statutory loss driven by a VCAT ruling, yet signs of sales recovery and a refreshed strategy offer a path forward.

Perpetual Limited reported a steady FY25 with underlying profit after tax of $204.1 million, revenue growth across all segments, and a net loss narrowed to $58.2 million. The firm’s refreshed strategy focuses on simplification, operational excellence, and measured growth investments amid evolving regulatory landscapes.

Perpetual Limited reported a steady underlying profit for FY25, achieving significant cost savings while navigating asset management outflows and advancing the sale of its Wealth Management division.

Dimerix Limited reported a 22% reduction in its FY2025 loss to $13.25 million, driven by strong licensing revenues and advancing its pivotal Phase 3 clinical trial for DMX-200. The company secured new global partnerships valued at up to AU$1.4 billion, bolstering its cash reserves and commercial prospects.

Perpetual Limited reported a resilient FY25 with a slight dip in underlying profit, offset by strong asset growth and progress on its Simplification Program and Wealth Management sale.

Lifestyle Communities reported a significant statutory loss for FY25, driven by legal provisions and asset write-downs, yet signs of recovery emerged in the second half with improved sales and cash flow.

Telix Pharmaceuticals has received a Complete Response Letter from the FDA for its TLX250-CDx diagnostic agent, citing manufacturing concerns. The company plans immediate remediation and maintains its 2025 revenue guidance.